Hankó Balázs Zoltán, Reszegi Csilla Andrea, Kumli Péter, Vincze Zoltán
Semmelweis Egyetem, Egyetemi Gyógyszertdár Gyógyszerügyi Szervezési Intézet, Budapest.
Acta Pharm Hung. 2005;75(2):77-86.
Type 2 diabetes is one of the biggest public health problems of our age. In the present study the authors analyse the development of the therapy of type 2 diabetic patients. National antidiabetic consumption data and data of National Health Insurance Fund Administration (OEP) were used. From OEP database definite method were used to choose 1002 type 2 diabetic patients. The Hungarian therapeutic practice develops according to guidelines of multi centered studies, and the consumption of antidiabetics dynamically increases. Increasing the number of patients who get insulin therapy and among patients who get oral antidiabetics more of them get insulin resistance decreasing therapy. However the out-of-date drugs (non-micronized glibenclamide, buformin) are still in daily therapy. The authors revealed the ratio of diet and drug (monotherapy, combination therapy) therapy, the higher use of Sulfanylurea monotherapy than recommended and the use of unreasonable combinations.
2型糖尿病是我们这个时代最大的公共卫生问题之一。在本研究中，作者分析了2型糖尿病患者的治疗发展情况。使用了全国抗糖尿病药物消费数据和国家健康保险基金管理局（OEP）的数据。从OEP数据库中采用特定方法选取了1002例2型糖尿病患者。匈牙利的治疗实践是按照多中心研究的指南发展的，抗糖尿病药物的消费量动态增加。接受胰岛素治疗的患者数量增加，在接受口服抗糖尿病药物治疗的患者中，更多的人接受胰岛素抵抗降低治疗。然而，过时的药物（非微粉化格列本脲、二甲双胍）仍在日常治疗中使用。作者揭示了饮食和药物（单一疗法、联合疗法）治疗的比例、磺脲类单一疗法的使用高于推荐水平以及不合理联合用药的情况。
